Healthcare Technology

NVIDIA's BioNeMo platform has locked in partnerships with Eli Lilly and Thermo Fisher Scientific for AI-driven drug discovery infrastructure, mirroring its data center dominance in the pharmaceutical R&D sector. The deals position NVIDIA as the computational substrate provider as global pharma shifts from hypothesis-driven research to foundation model-based discovery, with five specialized biotech AI platforms launching simultaneously.

NVIDIA's BioNeMo platform is being deployed by major pharmaceutical companies worldwide for AI-driven drug discovery in early 2026. Thermo Fisher and Eli Lilly lead global adoption, integrating the GPU-powered platform into lab automation workflows. The enterprise-scale rollout marks a shift from pilot programs to operational deployment across the international pharmaceutical sector.

NVIDIA's BioNeMo platform is being adopted by pharmaceutical giants Thermo Fisher and Eli Lilly to accelerate AI-driven drug discovery. The partnerships position NVIDIA's GPU infrastructure as the computing foundation for the global pharmaceutical R&D industry, mirroring its dominance in large language model infrastructure.

Eli Lilly and Thermo Fisher Scientific have integrated NVIDIA's BioNeMo platform into drug discovery workflows, marking a shift in how pharmaceutical companies automate research. The platform provides pre-trained AI models for molecular biology tasks, positioning NVIDIA beyond hardware sales into software infrastructure. The adoption spans established pharmaceutical giants and emerging biotech firms across global markets.